BeStock  
Stocks › Biotechnology › NTLA

Intellia Therapeutics NTLA

US equityMarket cap rank #2922BiotechnologyGene Editing
$10.00 +$0.48 (+5.04%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.00 +0.01%
Open$9.34
Prev close$9.52
Day range$9.30 – $10.40
Volume15.19M
Market cap$1.40B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-2.9x
CheapRich

Above its usual level · 78th percentile, 5-year average -6.9x

Price / book2.2x
CheapRich

Below its usual level · 33rd percentile, 5-year average 2.9x

#3275 of 5330 stocks by PB (1 = cheapest)

Price / sales25.7x
CheapRich

Below its usual level · 20th percentile, 5-year average 65.6x

#4776 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-51x-33x-14x4xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$27.00
Price vs. fair value-63.0%Trading below the estimate
Star rating★★★★★
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 2.22 – 2.92 33% (cheaper than usual) #3275 of 5330 (1 = cheapest)
PE -2.90 -3.03 -6.90 78% (pricier than usual) –
PS 25.74 20.68 65.59 20% (cheaper than usual) #4776 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on NTLA.

Sign in to join the discussion.

Scroll to Top